AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...
AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline ​for the drugmaker's ...
The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak.
May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class of blood pressure ...
AstraZeneca makes proposals to cut U.S. drug price cuts CEO Soriot says also considering direct sales to customers AstraZeneca maintains annual outlook Second-quarter sales and profit beat analysts' ...
By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the ...
By Maggie Fick LONDON (Reuters) -AstraZeneca CEO Pascal Soriot looked relaxed standing in the Oval Office on Friday as U.S. President Donald Trump unveiled a medicine deal that will lower drug prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results